Table 2.
Cohort characteristics at the individual level. The cross-sectional anthropometric and biochemistry background information were extracted from the most recent hospital contact, i.e. between January 1, 2019, and May 31, 2023. Subsequently, the pharmacotherapy data were extracted through the medical chart reviews. The term present treatment states that the treatment was ongoing at the most recent hospital contact.
| Cross-sectional background anthropometric and biochemistry information |
Follow-up on pharmacotherapies |
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | Disease | Sex | Age group(yr) | Time sincediagnosis(yr) | Birth-place | ALT (U/l) |
AST (U/l) |
Alkaline phosphatase (U/L) | Bilirubin (µmol/l) |
FIB4 | BMI (kg/m2) |
prednisolone | azathioprine | mycophenolic acid | UDCA | Treatment response |
| 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
AIH AIH AIH AIH AIH AIH AIH AIH/PBC AIH/PBC AIH/PBC AIH/PBC PBC PBC PBC |
M M F F M F F M F F F F F F |
≥60 ≥60 ≥60 ≥60 ≥60 ≥60 ≥60 <60 ≥60 <60 ≥60 ≥60 ≥60 <60 |
6.6 5.4 7.5 8.4 2.3 5.9 2.8 18.9 14.8 14.7 14.8 15.5 2.7 10.8 |
GR GR GR GR GR N/R GR GR GR GR DK GR GR GR |
43 33 28 39 53 28 28 91 69 125 52 111 58 12 |
43 25 N/R 29 31 31 29 55 42 81 45 176 52 21 |
52 88 109 114 35 91 109 157 175 129 153 521 318 70 |
27 7 8 27 34 14 31 24 8 17 32 155 9 7 |
2.69 1.12 N/R 1.33 1.35 2.09 1.18 1.00 2.28 1.61 2.41 4.43 1.39 N/R |
29.1 25.0 45.2 N/R 32.3 44.0 30.8 31.4 22.8 28.9 N/R 24.9 18.7 N/R |
present present present previously present previously present present present N/R N/R never never never |
present present never present present previously never present present present present never never never |
never never never never never present never never never never never never never never |
never never never never never never never present present present present present present present |
Complete Relapsing Complete Complete Complete Complete Complete Relapsing Partial Complete Partial Non-resp. Non-resp. Responder |
Abbreviations: AIH, autoimmune hepatitis; PBC, primary biliary cholangitis; M, male; F, female; yr, years; GR, Greenland; DK, Denmark; N/R, not reported; ALT, alanine aminotransferase; AST, aspartate aminotransferase; FIB4, fibrosis 4; BMI, body mass index; UDCA, ursodeoxycholic acid; Non-resp., non-responder.